Deutsch English Français

Contact

EP3404040

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3404040

EP3404040 - ANTI-MYL9 ANTIBODY [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 06.01.2023 Database last updated on 17.07.2024
Former	The patent has been granted Status updated on 28.01.2022
Former	Grant of patent is intended Status updated on 11.11.2021
Former	Examination is in progress Status updated on 17.09.2021
Former	Grant of patent is intended Status updated on 05.07.2021
Former	Examination is in progress Status updated on 06.04.2020
Former	Request for examination was made Status updated on 19.10.2018
Former	The international publication has been made Status updated on 21.07.2017
Most recent event Tooltip	14.06.2024	Lapse of the patent in a contracting state New state(s): MC	published on 17.07.2024 [2024/29]
Applicant(s)	For all designated states National University Corporation Chiba University 1-33, Yayoi-cho Inage-ku Chiba-shi, Chiba 263-8522 / JP
	For all designated states Eisai R&D Management Co., Ltd. 4-6-10 Koishikawa Bunkyo-ku Tokyo 112-8088 / JP
	[N/P]
Former [2018/47]	For all designated states National University Corporation Chiba University 1-33, Yayoi-cho Inage-ku Chiba-shi, Chiba 263-8522 / JP
	For all designated states Eisai R&D Management Co., Ltd. 4-6-10 Koishikawa Bunkyo-ku Tokyo 112-8088 / JP
Inventor(s)	01 / NAKAYAMA, Toshinori c/o Graduate School of Medicine National University Corporation Chiba University 1-8-1 Inohana Chuo-ku Chiba-shi Chiba 260-8670 / JP
	02 / KIMURA, Motoko c/o Graduate School of Medicine National University Corporation Chiba University 1-8-1 Inohana Chuo-ku Chiba-shi Chiba 260-8670 / JP
	03 / HAYASHIZAKI, Koji c/o Graduate School of Medicine National University Corporation Chiba University 1-8-1 Inohana Chuo-ku Chiba-shi Chiba 260-8670 / JP
	04 / HIRAYAMA, Toshifumi C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	05 / KAKUTA, Jungo C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	06 / SAKAMOTO, Yoshimasa C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	07 / GEJIMA, Ryu C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	08 / TOKITA, Daisuke C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	09 / MURAMOTO, Kenzo C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	10 / IMAI, Toshio C/O KAN Research Institute Inc. 6-8-2 Minatojima-minamimachi Chuo-ku Kobe-shi Hyogo 650-0047 / JP
	[2018/47]
Representative(s)	Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	[2018/47]
Application number, filing date	17738420.3	11.01.2017
	[2018/47]
	WO2017JP00605
Priority number, date	JP20160003429	12.01.2016 Original published format: JP 2016003429
	[2018/47]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2017122666
	Date:	20.07.2017
	Language:	JA
	[2017/29]
	Type:	A1 Application with search report
	No.:	EP3404040
	Date:	21.11.2018
	Language:	EN
	[2018/47]
	Type:	B1 Patent specification
	No.:	EP3404040
	Date:	02.03.2022
	Language:	EN
	[2022/09]
Search report(s)	International search report - published on:	JP	20.07.2017
	(Supplementary) European search report - dispatched on:	EP	08.07.2019
Classification	IPC:	C07K16/18, A61K39/395, A61P1/04, A61P11/00, A61P35/00, A61P37/08, C07K16/46, C12N15/09	[2018/47]
	CPC:	A61P37/08 (EP,RU,US); A61K39/395 (EP,IL,RU,US); C07K16/46 (EP,IL,US); A61K39/3955 (US); A61P1/00 (RU); A61P1/04 (EP,US); (+) A61P11/00 (EP,RU,US); A61P35/00 (EP,RU,US); A61P37/02 (EP,US); C07K16/18 (EP,IL,RU,US); C07K16/2803 (US); C12N15/09 (EP,IL,US); C07K14/4716 (US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/47]
Extension states	BA	18.06.2018
	ME	18.06.2018
Validation states	MA	18.06.2018
	MD	18.06.2018
Title	German:	ANTI-MYL9-ANTIKÖRPER	[2018/47]
	English:	ANTI-MYL9 ANTIBODY	[2018/47]
	French:	ANTICORPS ANTI-MYL9	[2018/47]
Entry into regional phase	18.06.2018	Translation filed
	18.06.2018	National basic fee paid
	18.06.2018	Search fee paid
	18.06.2018	Designation fee(s) paid
	18.06.2018	Examination fee paid
Examination procedure	deleted	Date on which the examining division has become responsible
	18.06.2018	Examination requested [2018/47]
	23.01.2020	Amendment by applicant (claims and/or description)
	09.04.2020	Despatch of a communication from the examining division (Time limit: M04)
	31.07.2020	Reply to a communication from the examining division
	14.10.2020	Despatch of a communication from the examining division (Time limit: M04)
	12.02.2021	Reply to a communication from the examining division
	06.07.2021	Communication of intention to grant the patent
	16.09.2021	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	12.11.2021	Communication of intention to grant the patent
	21.12.2021	Fee for grant paid
	21.12.2021	Fee for publishing/printing paid
	21.12.2021	Receipt of the translation of the claim(s)
Opposition(s)	05.12.2022	No opposition filed within time limit [2023/06]
Fees paid	Renewal fee
	22.01.2019	Renewal fee patent year 03
	23.01.2020	Renewal fee patent year 04
	25.01.2021	Renewal fee patent year 05
	25.01.2022	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AL	02.03.2022
	AT	02.03.2022
	CZ	02.03.2022
	DK	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	MC	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SI	02.03.2022
	SK	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	IS	02.07.2022
	PT	04.07.2022
	[2024/29]
Former [2023/10]	AL	02.03.2022
	AT	02.03.2022
	CZ	02.03.2022
	DK	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SI	02.03.2022
	SK	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	IS	02.07.2022
	PT	04.07.2022
Former [2023/07]	AL	02.03.2022
	AT	02.03.2022
	CZ	02.03.2022
	DK	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SK	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	IS	02.07.2022
	PT	04.07.2022
Former [2023/01]	AL	02.03.2022
	AT	02.03.2022
	CZ	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SK	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	IS	02.07.2022
	PT	04.07.2022
Former [2022/51]	AT	02.03.2022
	CZ	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SK	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	IS	02.07.2022
	PT	04.07.2022
Former [2022/49]	AT	02.03.2022
	CZ	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SK	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	PT	04.07.2022
Former [2022/48]	AT	02.03.2022
	CZ	02.03.2022
	EE	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	PT	04.07.2022
Former [2022/47]	AT	02.03.2022
	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RO	02.03.2022
	RS	02.03.2022
	SM	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
	PT	04.07.2022
Former [2022/39]	FI	02.03.2022
	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RS	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
Former [2022/36]	HR	02.03.2022
	LT	02.03.2022
	LV	02.03.2022
	PL	02.03.2022
	RS	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
	GR	03.06.2022
Former [2022/35]	HR	02.03.2022
	LT	02.03.2022
	RS	02.03.2022
	BG	02.06.2022
	NO	02.06.2022
Former [2022/33]	LT	02.03.2022
	NO	02.06.2022
Documents cited:	Search	[IP] - KOJI HAYASHIZAKI ET AL, "Myosin light chains 9 and 12 are functional ligands for CD69 that regulate airway inflammation", SCIENCE IMMUNOLOGY, US, (20160916), vol. 1, no. 3, doi:10.1126/sciimmunol.aaf9154, ISSN 2470-9468, pages eaaf9154 - eaaf9154, XP055335879 [IP] 1-20 * the whole document * DOI: http://dx.doi.org/10.1126/sciimmunol.aaf9154
		[I] - YA-QIANG HUANG ET AL, "Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer", MEDICAL ONCOLOGY, GB, (20140101), vol. 31, no. 1, doi:10.1007/s12032-013-0820-4, ISSN 1357-0560, XP055337472 [I] 1-20 * page 820 * DOI: http://dx.doi.org/10.1007/s12032-013-0820-4
	International search	[A]WO2008105058 (ASAHI KASEI PHARMA CORP [JP], et al) [A] 1-20* , & US 2010/0093789 A1 *;
		[YA]WO2010123012 (KYOWA HAKKO KIRIN CO LTD [JP], et al) [YA] 1-4, 6-20/5 * , paragraph [0011] & US 2012/0087927 A1 paragraph [0012] & EP 2423228 A1 *;
		[YA]WO2014192915 (UNIV CHIBA NAT UNIV CORP [JP]) [YA] 1-4, 6-20/5 * , claims 1 to 3; paragraphs [0046], [0055]; example 4 & US 2016/0102139 A1 claims 1 to 3; paragraphs [0069], [0078]; example 4 & EP 3006042 A1 *;
		[YA]WO2014205501 (UNIV MONASH [AU], et al) [YA] 1-4, 6-20/5 * , page 7, lines 16 to 26 & JP 2016-529213 A & US 2016/0145332 A1 & EP 3013858 A1 *;
		[YA]WO2015190538 (IDAC THERANOSTICS INC [JP]) [YA] 1-4, 6-20/5 * , paragraph [0006] (Family: none) *;
		[YA] - LUO XUE-GANG et al., "Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells", Cancer Letters, (20140000), vol. 344, pages 129 - 137, XP028826472 [YA] 1-4, 6-20/5 * , abstract * DOI: http://dx.doi.org/10.1016/j.canlet.2013.10.026
		[YA] - ISHIHARA S. et al., "Irradiation-tolerant lung cancer cells acquire invasive ability dependent on dephosphorylation of the myosin regulatory light chain", FEBS Letters, (20130000), vol. 587, pages 732 - 736, XP028998881 [YA] 1-4, 6-20/5 * , abstract * DOI: http://dx.doi.org/10.1016/j.febslet.2013.01.055
	by applicant	WO2014192915
		- TESTI, R. et al., Immunol. Today, (19940000), vol. 15, pages 479 - 483
		- MURATA, K. et al., "CD69-null mice protected from arthritis induced with anti-type II collagen antibodies", Int. Immunol., (20030000), vol. 15, pages 987 - 992
		- MIKI-HOSOKAWA, T. et al., "CD69 controls the pathogenesis of allergic airway inflammation", J. Immunol., (20090000), vol. 183, doi:doi:10.4049/jimmunol.0900646, pages 8203 - 8215, XP055219366 DOI: http://dx.doi.org/10.4049/jimmunol.0900646
		- "Genbank", Database accession no. NP 006088.2
		- "Genbank", Database accession no. NP_742116.1
		- AL-LAZIKANI et al., J. Molec. Biol., (19970000), vol. 273, pages 927 - 948
		- JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
		- RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327
		- VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
		- TSURUSHITA et al., Methods, (20050000), vol. 36, pages 69 - 83
		- CARTER et al., Proc. Natl. Acad. Set USA, (19920000), vol. 89, pages 4285 - 4289
		- PRESTA et al., J. Immunol., (19930000), vol. 151, pages 2623 - 2632
		- "Genbank", Database accession no. NP-006088.2
		- "Genbank", Database accession no. NP_034989.1
		- "Genbank", Database accession no. NP_000249.1
		- POWRIE et al., Int. Immunol., (19930000), vol. 5, pages 1461 - 1471
		- COOPER et al., Lab. Invest., (19930000), vol. 69, pages 238 - 249
		- "Genbank", Database accession no. NP_080340.2
		- "Genbank", Database accession no. NP_075891.1
		- "Genbank", Database accession no. NP_001289976.1
		- "Genbank", Database accession no. NP 001138416.1

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p